Enzene's new division is dedicated to offering comprehensive discovery services from start to finish. Enzene Biosciences has exciting news to share! They will be launching their Drug Discovery Division at the upcoming BIO 2024 International Convention in San Diego, Cali. The convention will take place from June 3–
Broken String Biosciences and the Francis Crick Institute have joined forces to investigate the relationship between genome stability and ALS Broken String Biosciences, a genomics company based in the UK, has joined forces with the Francis Crick Institute, a biomedical discovery institute, to broaden the uses of DNA break-mapping technology.
A team at Oxford Biomedica conducted studies that showed the effectiveness of using HIC to separate non-deamidated capsids from deamidated capsids. During a presentation at the American Society of Gene and Cell Therapy’s (ASGCT’s) 27th Annual Meeting, Alex Meola, associate director of AAV Downstream Process Development at Oxford
ProPharm and PBL have recently introduced the Cell Factory Box, a state-of-the-art cell factory manufacturing device that is fully automated and enclosed ProPharma, a US-based company specializing in regulatory, clinical, and compliance services for the life sciences industry, has recently introduced the Cell Factory Box (CF Box). Developed in collaboration
Mariana's collection of radioligand therapies will enhance Novartis' radioligand therapy pipeline.Mariana's collection of radioligand therapies will enhance Novartis' radioligand therapy pipeline. On May 2, 2024, Novartis made an announcement about their agreement to acquire Mariana Oncology. Mariana Oncology is a preclinical stage biotechnology
Important areas to consider for investment are manufacturing process improvements, quality management, and AI. With CPHI North America just around the corner, taking place at the Pennsylvania Convention Centre from May 7-9, 2024, industry experts are advising US-based contract development and manufacturing organizations (CDMOs), particularly those that are small to
Shanghai Henlius Biotech's initial biosimilar has already been granted approvals by the European Commission and National Medical Products Administration. Shanghai Henlius Biotech (Henlius), a biopharmaceutical company based in Shanghai, recently announced that the FDA has approved HERCESSI (HLX002; trastuzumab-strf), a trastuzumab biosimilar that was developed and manufactured by
Beqvez (fidanacogene elaparvovec-dzkt) is a gene therapy that offers a one-time solution for adults with hemophilia B. It enables them to produce factor IX on their own, eliminating the need for regular intravenous infusions. Pfizer's latest breakthrough in gene therapy, Beqvez (fidanacogene elaparvovec-dzkt), has received FDA approval for
During INTERPHEX 2024, Wenyu Zhang, PhD, discussed the latest developments in the aseptic industry and highlighted important factors that companies need to take into account when making decisions. At INTERPHEX 2024 in New York City, Wenyu Zhang, PhD, R&D Director, Berkshire Corporation, delivered a presentation on the latest
The collaboration will prioritize the development of cancer vaccine candidates for both hematological and solid tumor indications, to address unmet medical needs. CureVac, a biopharmaceutical company, recently announced a partnership with The University of Texas MD Anderson Cancer Center. This collaboration aims to advance cancer patient care, research, education, and
Lonza and Acumen Pharmaceuticals have entered into a partnership to produce sabirnetug, a monoclonal antibody that is currently in Phase II development for the treatment of Alzheimer's disease. Acumen Pharmaceuticals recently announced a collaboration agreement with Lonza. This agreement involves Lonza manufacturing sabirnetug (ACU193), a monoclonal antibody that
Charles River has secured two deals to provide plasmid DNA manufacturing services. One deal is with Axovia Therapeutics for their gene therapy under development, while the other is with Ship of Theseus for their lead candidate. Charles River Laboratories International has established manufacturing agreements with Axovia Therapeutics and Ship of